{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:43:59Z","timestamp":1769168639817,"version":"3.49.0"},"reference-count":201,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.pharmthera.2022.108121","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T19:57:03Z","timestamp":1643745423000},"page":"108121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences"],"prefix":"10.1016","volume":"235","author":[{"given":"Kimiyasu","family":"Shiraki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirou","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H.","family":"Kaszynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2022.108121_bb0005","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/1523-1747.ep12525745","article-title":"Ultraviolet light depletes surface markers of Langerhans cells","volume":"76","author":"Aberer","year":"1981","journal-title":"The Journal of Investigative Dermatology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0010","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1111\/jce.14772","article-title":"Clinical and cardiac characteristics of COVID-19 mortalities in a diverse New York City cohort","volume":"31","author":"Abrams","year":"2020","journal-title":"Journal of Cardiovascular Electrophysiology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0015","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19","volume":"383","author":"Ackermann","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0020","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.cell.2020.10.005","article-title":"Vascular disease and thrombosis in SARS-CoV-2-infected rhesus macaques","volume":"183","author":"Aid","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0025","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jiac.2017.02.001","article-title":"Acyclovir-resistant herpes simplex virus 1 infection early after allogeneic hematopoietic stem cell transplantation with T-cell depletion","volume":"23","author":"Akahoshi","year":"2017","journal-title":"Journal of Infection and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0030","series-title":"Treatment of herpes zoster in the immunocompetent host","author":"Albrecht","year":"2020"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0035","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0040","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03679","article-title":"Favipiravir elicits antiviral mutagenesis during virus replication in vivo","volume":"3","author":"Arias","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0045","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1442-200X.1993.tb03068.x","article-title":"Varicella-zoster virus replication site in internal organs of an otherwise healthy child with varicella and sudden death","volume":"35","author":"Asano","year":"1993","journal-title":"Acta Paediatrica Japonica"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0050","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/hep.23504","article-title":"Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials","volume":"51","author":"Awad","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0055","first-page":"25","article-title":"Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020","author":"Backer","year":"2020","journal-title":"Euro Surveillance"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0060","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/cid\/ciw571","article-title":"Clinical and virological characteristics of Ebola virus disease patients treated with Favipiravir (T-705)-Sierra Leone, 2014","volume":"63","author":"Bai","year":"2016","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0065","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJM198306163082404","article-title":"Acyclovir halts progression of herpes zoster in immunocompromised patients","volume":"308","author":"Balfour","year":"1983","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0070","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0075","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.57309","article-title":"SARS-CoV-2 (COVID-19) by the numbers","volume":"9","author":"Bar-On","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0080","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/35053110","article-title":"Role for a bidentate ribonuclease in the initiation step of RNA interference","volume":"409","author":"Bernstein","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0085","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.2174\/1381612823666170316123736","article-title":"Cytokines induced during influenza virus infection","volume":"23","author":"Betakova","year":"2017","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0090","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/infdis\/jiab039","article-title":"Evidence of severe acute respiratory syndrome coronavirus 2 replication and tropism in the lungs, airways, and vascular endothelium of patients with fatal coronavirus disease 2019: An autopsy case series","volume":"223","author":"Bhatnagar","year":"2021","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.puhe.2020.05.047","article-title":"Children\u2019s mortality from COVID-19 compared with all-deaths and other relevant causes of death: Epidemiological information for decision-making by parents, teachers, clinicians and policymakers","volume":"185","author":"Bhopal","year":"2020","journal-title":"Public Health"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0100","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S1473-3099(20)30287-5","article-title":"Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: A retrospective cohort study","volume":"20","author":"Bi","year":"2020","journal-title":"The Lancet Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0105","doi-asserted-by":"crossref","first-page":"422","DOI":"10.15585\/mmwr.mm6914e4","article-title":"Coronavirus disease 2019 in children - United States, February 12-April 2, 2020","volume":"69","author":"Bialek","year":"2020","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0110","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1001\/jama.2020.8707","article-title":"Nasal gene expression of angiotensin-converting enzyme 2 in children and adults","volume":"323","author":"Bunyavanich","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0115","first-page":"1192","article-title":"Experimental treatment with Favipiravir for COVID-19: An open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering (Beijing)"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0120","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/aje\/kwm375","article-title":"Time lines of infection and disease in human influenza: A review of volunteer challenge studies","volume":"167","author":"Carrat","year":"2008","journal-title":"American Journal of Epidemiology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0125","author":"CDC"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0130","series-title":"Seasonal Influenza (Flu)","article-title":"Influenza antiviral medications: Summary for clinicians","author":"CDC","year":"2021"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0135","series-title":"COVID-19 vaccination","article-title":"Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States","author":"CDC","year":"2021"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0140","series-title":"Variants and genomic surveillance for SARS-CoV-2","article-title":"SARS-CoV-2 variant classifications and definitions","author":"CDC","year":"2021"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0145","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0150","article-title":"Favipiravir versus Arbidol for COVID-19: A randomized clinical trial","author":"Chen","year":"2020","journal-title":"medRxiV"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0155","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/jamainternmed.2020.2020","article-title":"Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset","volume":"180","author":"Cheng","year":"2020","journal-title":"JAMA Internal Medicine"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0160","series-title":"National health commission of the People\u2019s Republic of China","article-title":"Several drugs against novel coronavirus already in clinical trials: Official","author":"China, N. H. C. O. T. P. S. R. O","year":"2020"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0165","series-title":"China CDC weekly (Vol. 2, pp. 113\u2013122)","article-title":"The epidemiological characteristics of an outbreak of 2019 Novel Coronavirus Diseases (COVID-19) \u2014 China, 2020","author":"ChinaCDC, T. N. C. P. E. R. E. T., CCDC","year":"2020"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antiviral Research"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0175","series-title":"Conference on retroviruses and opportunistic infections (pp. 144, No. 390): International antiviral society-USA","article-title":"Multicenter, open-labeled efficacy study of AVIFAVIR in patients with COVID-19","author":"Corritori","year":"2021"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0180","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1126\/science.368.6490.455","article-title":"The mystery of the pandemic's 'happy hypoxia'","volume":"368","author":"Couzin-Frankel","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nature Microbiology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0190","doi-asserted-by":"crossref","first-page":"20231","DOI":"10.1074\/jbc.R000002200","article-title":"Purine phosphoribosyltransferases","volume":"275","author":"Craig","year":"2000","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0195","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1111\/ajt.16185","article-title":"COVID-19 and kidney transplantation: Results from the TANGO international transplant consortium","volume":"20","author":"Cravedi","year":"2020","journal-title":"American Journal of Transplantation"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0200","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jmii.2017.03.004","article-title":"Characterization of susceptibility variants of poliovirus grown in the presence of favipiravir","volume":"51","author":"Daikoku","year":"2018","journal-title":"Journal of Microbiology, Immunology, and Infection"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0205","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jdermsci.2016.02.006","article-title":"Subclinical generation of acyclovir-resistant herpes simplex virus with mutation of homopolymeric guanosine strings during acyclovir therapy","volume":"82","author":"Daikoku","year":"2016","journal-title":"Journal of Dermatological Science"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0210","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1254\/jphs.14156SC","article-title":"Characterization of susceptibility variants of influenza virus grown in the presence of T-705","volume":"126","author":"Daikoku","year":"2014","journal-title":"Journal of Pharmacological Sciences"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108121_bb0215","doi-asserted-by":"crossref","first-page":"e00110","DOI":"10.1128\/JVI.00110-21","article-title":"SARS-CoV-2 causes severe epithelial inflammation and barrier dysfunction","volume":"95","author":"Deinhardt-Emmer","year":"2021","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0220","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antiviral Research"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0225","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1093\/jac\/dku209","article-title":"Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral","volume":"69","author":"Delang","year":"2014","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0230","series-title":"Favipiravir observational study interim report (2nd report)","author":"Doi","year":"2020"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0235","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-0702","article-title":"Epidemiology of COVID-19 among children in China","volume":"145","author":"Dong","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0240","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/000348949410300111","article-title":"Nasal and otologic effects of experimental influenza A virus infection","volume":"103","author":"Doyle","year":"1994","journal-title":"The Annals of Otology, Rhinology, and Laryngology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0245","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1126\/science.abg5827","article-title":"Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2","volume":"373","author":"Drayman","year":"2021","journal-title":"Science"},{"issue":"Suppl 1","key":"10.1016\/j.pharmthera.2022.108121_bib989","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/510206","article-title":"Recommendations for the management of herpes zoster.","volume":"44","author":"Dworkin","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0250","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S1474-4422(20)30221-0","article-title":"Neurological associations of COVID-19","volume":"19","author":"Ellul","year":"2020","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0255","series-title":"Moderna COVID-19 vaccine","author":"FDA","year":"2020"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0260","series-title":"Pfizer-BioNTech COVID-19 vaccine","author":"FDA","year":"2020"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108588","article-title":"SARS-CoV-2 infections in children and young people","volume":"220","author":"Felsenstein","year":"2020","journal-title":"Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0270","article-title":"Molnupiravir, an oral antiviral treatment for COVID-19","author":"Fischer","year":"2021","journal-title":"medRxiV"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0275","article-title":"Cytokine storm and histopathological findings in 60 cases of COVID-19-related death: From viral load research to immunohistochemical quantification of major players IL-1beta, IL-6, IL-15 and TNF-alpha","author":"Frisoni","year":"2021","journal-title":"Forensic Science, Medicine, and Pathology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0280","series-title":"AVIGAN tablets 200mg package insert","author":"Fujifim","year":"2019"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0285","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jiac.2021.04.013","article-title":"Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients","volume":"27","author":"Fujii","year":"2021","journal-title":"Journal of Infection and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0290","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1099\/vir.0.038414-0","article-title":"Infection of human alveolar macrophages by human coronavirus strain 229E","volume":"93","author":"Funk","year":"2012","journal-title":"The Journal of General Virology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0295","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Research"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0300","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0305","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antiviral Research"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0310","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41581-020-00349-4","article-title":"CKD is a key risk factor for COVID-19 mortality","volume":"16","author":"Gansevoort","year":"2020","journal-title":"Nature Reviews. Nephrology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0315","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1542\/peds.54.2.136","article-title":"Photodistribution of viral exanthems","volume":"54","author":"Gilchrest","year":"1974","journal-title":"Pediatrics"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0320","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01217-18","article-title":"Determining the mutation bias of Favipiravir in influenza virus using next-generation sequencing","volume":"93","author":"Goldhill","year":"2019","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0325","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.1811345115","article-title":"The mechanism of resistance to favipiravir in influenza","volume":"115","author":"Goldhill","year":"2018","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008937","article-title":"Favipiravir-resistant influenza A virus shows potential for transmission","volume":"17","author":"Goldhill","year":"2021","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0335","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02479-20","article-title":"AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19","volume":"65","author":"Good","year":"2021","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0340","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1542\/peds.68.5.735","article-title":"Variation on a theme by Fenner: The pathogenesis of chickenpox","volume":"68","author":"Grose","year":"1981","journal-title":"Pediatrics"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0345","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41569-020-00469-1","article-title":"Thrombocytopathy and endotheliopathy: Crucial contributors to COVID-19 thromboinflammation","volume":"18","author":"Gu","year":"2021","journal-title":"Nature Reviews. Cardiology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0350","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1089\/vim.2019.0032","article-title":"Role of the innate cytokine storm induced by the influenza A virus","volume":"32","author":"Gu","year":"2019","journal-title":"Viral Immunology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0355","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1074\/jbc.M410592200","article-title":"Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus","volume":"280","author":"Guillot","year":"2005","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0360","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1056\/NEJMoa2105000","article-title":"Vaccine breakthrough infections with SARS-CoV-2 variants","volume":"384","author":"Hacisuleyman","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0365","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3201\/eid2606.200516","article-title":"Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, United States","volume":"26","author":"Harcourt","year":"2020","journal-title":"Emerging Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0370","doi-asserted-by":"crossref","first-page":"11022","DOI":"10.1038\/s41598-021-90551-6","article-title":"The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials","volume":"11","author":"Hassanipour","year":"2021","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0375","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir Marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0380","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0014-4827(61)90192-6","article-title":"The serial cultivation of human diploid cell strains","volume":"25","author":"Hayflick","year":"1961","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0385","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jhep.2009.12.039","article-title":"Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy","volume":"52","author":"Hofer","year":"2010","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0390","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1126\/science.abe8499","article-title":"SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo","volume":"370","author":"Hou","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0395","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0400","series-title":"The ICTV Coronaviridae study group (the ICTV Study Group Ed.)","article-title":"Naming the 2019 coronavirus","author":"ICTV","year":"2020"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0405","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0166-3542(98)00057-6","article-title":"Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants","volume":"40","author":"Ida","year":"1999","journal-title":"Antiviral Research"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0410","article-title":"Chest CT findings in cases from the cruise ship \u201cdiamond princess\u201d with coronavirus disease 2019 (COVID-19)","volume":"2","author":"Inui","year":"2020","journal-title":"Radiology: Cardiothoracic Imaging"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0415","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/cid\/ciaa1176","article-title":"AVIFAVIR for treatment of patients with moderate coronavirus disease 2019 (COVID-19): Interim results of a phase II\/III multicenter randomized clinical trial","volume":"73","author":"Ivashchenko","year":"2021","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0420","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S1473-3099(15)00228-5","article-title":"Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: A case-series of health-care workers","volume":"15","author":"Jacobs","year":"2015","journal-title":"The Lancet Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2022.108121_bib986","doi-asserted-by":"crossref","first-page":"e68347","DOI":"10.1371\/journal.pone.0068347","article-title":"The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5\u2019-triphosphate towards influenza A virus polymerase.","volume":"8","author":"Jin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0425","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1084\/jem.142.4.864","article-title":"Immunologic injury in measles virus infection. II. Suppression of immune injury through antigenic modulation","volume":"142","author":"Joseph","year":"1975","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0430","doi-asserted-by":"crossref","first-page":"26955","DOI":"10.1073\/pnas.2014441117","article-title":"Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity","volume":"117","author":"Kaptein","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0435","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/1346-8138.13948","article-title":"Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study","volume":"44","author":"Kawashima","year":"2017","journal-title":"The Journal of Dermatology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0440","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1126\/science.401547","article-title":"Congenital anomalies induced in hamster embryos with ribavirin","volume":"195","author":"Kilham","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0445","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(04)16934-1","article-title":"Resistant influenza A viruses in children treated with oseltamivir: Descriptive study","volume":"364","author":"Kiso","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0450","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1097\/00006454-199009001-00008","article-title":"Effects of exposure to high concentrations of ribavirin in developing embryos","volume":"9","author":"Kochhar","year":"1990","journal-title":"The Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0455","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00006454-200205000-00037","article-title":"Safety issues related to the administration of ribavirin","volume":"21","author":"Krilov","year":"2002","journal-title":"The Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0460","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1128\/JVI.79.5.2651-2658.2005","article-title":"Varicella-zoster virus pathogenesis and immunobiology: New concepts emerging from investigations with the SCIDhu mouse model","volume":"79","author":"Ku","year":"2005","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0465","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0014-2999(03)02036-3","article-title":"Cytokine-regulatory activity and therapeutic efficacy of cinnamyl derivatives in endotoxin shock","volume":"474","author":"Kurokawa","year":"2003","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0470","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/(SICI)1096-9071(199610)50:2<152::AID-JMV8>3.0.CO;2-9","article-title":"Cascade of fever production in mice infected with influenza virus","volume":"50","author":"Kurokawa","year":"1996","journal-title":"Journal of Medical Virology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0475","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/s41591-020-1038-6","article-title":"A dynamic COVID-19 immune signature includes associations with poor prognosis","volume":"26","author":"Laing","year":"2020","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009500","article-title":"The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways","volume":"17","author":"Laporte","year":"2021","journal-title":"PLoS Pathogens"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108121_bb0485","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7326\/M20-2428","article-title":"Loss of smell and taste in 2013 European patients with mild to moderate COVID-19","volume":"173","author":"Lechien","year":"2020","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0490","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0495","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1002\/acn3.51210","article-title":"Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients","volume":"7","author":"Liotta","year":"2020","journal-title":"Annals of Clinical Translational Neurology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0500","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European conference on infections in leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"The Lancet Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0505","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamacardio.2020.1286","article-title":"Potential effects of coronaviruses on the cardiovascular system: A review","volume":"5","author":"Madjid","year":"2020","journal-title":"JAMA Cardiology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0510","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature08283","article-title":"An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA","volume":"461","author":"Maida","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0515","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China","volume":"77","author":"Mao","year":"2020","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0520","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jama.2014.7999","article-title":"HIV prevention in clinical care settings: 2014 recommendations of the international antiviral society-USA panel","volume":"312","author":"Marrazzo","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0525","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3390\/v4050901","article-title":"Protective role of toll-like receptor 3-induced type I interferon in murine coronavirus infection of macrophages","volume":"4","author":"Mazaleuskaya","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0530","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/cid\/cit725","article-title":"The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts","volume":"58","author":"Memoli","year":"2014","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0535","author":"Merck & Co., I"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0540","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1001\/jamaneurol.2020.2730","article-title":"Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza","volume":"77","author":"Merkler","year":"2020","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0545","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/1523-1747.ep12495372","article-title":"Detection of viral DNA within skin of healed recurrent herpes simplex infection and erythema multiforme lesions","volume":"98","author":"Miura","year":"1992","journal-title":"The Journal of Investigative Dermatology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0550","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1365-2133.2005.06849.x","article-title":"The role of CD4 and CD8 cytotoxic T lymphocytes in the formation of viral vesicles","volume":"153","author":"Morizane","year":"2005","journal-title":"The British Journal of Dermatology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0555","article-title":"Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP","volume":"118","author":"Naydenova","year":"2021","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0560","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antiviral Research"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102367","article-title":"Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment","volume":"24","author":"Ohashi","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0570","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jmv.10562","article-title":"Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus","volume":"72","author":"Okuda","year":"2004","journal-title":"Journal of Medical Virology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0575","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0022-5193(73)90198-7","article-title":"A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon","volume":"41","author":"Olovnikov","year":"1973","journal-title":"Journal of Theoretical Biology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0580","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.1111\/1346-8138.16027","article-title":"Improvement of acyclovir-resistant herpes zoster infection by amenamevir","volume":"48","author":"Onaka","year":"2021","journal-title":"The Journal of Dermatology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0585","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/adc.78.1.95","article-title":"Susceptibilities to aciclovir in viral isolates from children with varicella","volume":"78","author":"Ozaki","year":"1998","journal-title":"Archives of Disease in Childhood"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0590","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/molehr\/gat055","article-title":"Telomere length and telomerase activity during oocyte maturation and early embryo development in mammalian species","volume":"20","author":"Ozturk","year":"2014","journal-title":"Molecular Human Reproduction"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0595","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/0956462415580512","article-title":"2014 UK national guideline for the management of anogenital herpes","volume":"26","author":"Patel","year":"2015","journal-title":"International Journal of STD & AIDS"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0600","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1177\/0956462417727194","article-title":"2017 European guidelines for the management of genital herpes","volume":"28","author":"Patel","year":"2017","journal-title":"International Journal of STD & AIDS"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0605","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1172\/JCI137647","article-title":"SARS-CoV-2: A storm is raging","volume":"130","author":"Pedersen","year":"2020","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0610","article-title":"Structural basis of SARS-CoV-2 polymerase inhibition by Favipiravir","volume":"2","author":"Peng","year":"2021","journal-title":"Innovation (N Y)"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0615","author":"Pfizer Inc"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104878","article-title":"In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2","volume":"181","author":"Pizzorno","year":"2020","journal-title":"Antiviral Research"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0625","series-title":"Evaluation and licensing division, pharmaceutical and food safety bureau Ministry of Health, Labour and Welfare","article-title":"Report on the deliberation results","author":"PMDA","year":"2014"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0630","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3389\/fimmu.2019.02161","article-title":"A single-stranded oligonucleotide inhibits toll-like receptor 3 activation and reduces influenza A (H1N1) infection","volume":"10","author":"Poux","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0635","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1056\/NEJMc2011400","article-title":"Multiorgan and renal tropism of SARS-CoV-2","volume":"383","author":"Puelles","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0640","first-page":"260","article-title":"European recommendations for the management of healthcare workers occupationally exposed to hepatitis B virus and hepatitis C virus","volume":"10","author":"Puro","year":"2005","journal-title":"Euro Surveillance"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0645","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s41564-020-0770-5","article-title":"A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology","volume":"5","author":"Rambaut","year":"2020","journal-title":"Nature Microbiology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0650","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41564-021-00872-5","article-title":"Addendum: A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology","volume":"6","author":"Rambaut","year":"2021","journal-title":"Nature Microbiology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0655","article-title":"Cytomegalovirus in solid organ transplant recipients-guidelines of the American Society of Transplantation infectious diseases community of practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0660","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2215-0366(20)30203-0","article-title":"Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic","volume":"7","author":"Rogers","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0665","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41467-021-22580-8","article-title":"Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model","volume":"12","author":"Rosenke","year":"2021","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0670","series-title":"The 56th annual congress of the Japan society for transplantation (pp. UP2-1)","article-title":"An early treatment with favipiravir for quickly diagnosed COVID-19 in a kidney transplantation recipient","author":"Sakai","year":"2020"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0675","doi-asserted-by":"crossref","DOI":"10.3390\/cells8121564","article-title":"The expression of miRNAs in human ovaries, oocytes, extracellular vesicles, and early embryos: a systematic review","volume":"8","author":"Salas-Huetos","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2022.108121_bib987","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1128\/AAC.00649-13","article-title":"Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase.","volume":"57","author":"Sangawa","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0680","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-020-18463-z","article-title":"Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis","volume":"11","author":"Shannon","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0685","doi-asserted-by":"crossref","DOI":"10.1007\/s40121-021-00517-4","article-title":"Efficacy and safety of Favipiravir in moderate COVID-19 pneumonia patients without oxygen therapy: A randomized, phase III clinical trial","author":"Shinkai","year":"2021","journal-title":"Infectious Disease and Therapy"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0690","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1358\/dot.2017.53.11.2724803","article-title":"Helicase-primase inhibitor amenamevir for herpesvirus infection: Towards practical application for treating herpes zoster","volume":"53","author":"Shiraki","year":"2017","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0695","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-981-10-7230-7_6","article-title":"Antiviral drugs against Alphaherpesvirus","volume":"1045","author":"Shiraki","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.pharmthera.2022.108121_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0705","doi-asserted-by":"crossref","first-page":"8172","DOI":"10.1128\/JVI.00435-11","article-title":"Neutralizing anti-gH antibody of varicella-zoster virus modulates distribution of gH and induces gene regulation, mimicking latency","volume":"85","author":"Shiraki","year":"2011","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0710","first-page":"30","article-title":"Towards avigan approval for coronavirus infection (COVID-19)","volume":"5036","author":"Shiraki","year":"2020","journal-title":"Japanese Medical Journal"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0715","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0166-3542(92)90039-8","article-title":"Comparison of antiviral assay methods using cell-free and cell-associated varicella-zoster virus","volume":"18","author":"Shiraki","year":"1992","journal-title":"Antiviral Research"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0720","first-page":"17","article-title":"Isolation of drug resistant mutants of varicella-zoster virus: Cross resistance of acyclovir resistant mutants with phosphonoacetic acid and bromodeoxyuridine","volume":"26","author":"Shiraki","year":"1983","journal-title":"Biken Journal"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0725","first-page":"1","article-title":"Emergence of varicella-zoster virus resistance to acyclovir: Epidemiology, prevention, and treatment","author":"Shiraki","year":"2021","journal-title":"Expert Review of Anti-Infective Therapy"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104829","article-title":"Viral ribonucleotide reductase attenuates the anti-herpes activity of acyclovir in contrast to amenamevir","volume":"180","author":"Shiraki","year":"2020","journal-title":"Antiviral Research"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0735","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/infdis\/149.4.501","article-title":"Biologic and immunologic characterization of the soluble skin-test antigen of varicella-zoster virus","volume":"149","author":"Shiraki","year":"1984","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0740","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000221861","article-title":"In vitro and in vivo effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) on types 1 and 3 parainfulenza virus infections","volume":"21","author":"Sidwell","year":"1975","journal-title":"Chemotherapy"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0745","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s40264-017-0566-6","article-title":"The ribavirin pregnancy registry: An interim analysis of potential teratogenicity at the mid-point of Enrollment","volume":"40","author":"Sinclair","year":"2017","journal-title":"Drug Safety"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0860","first-page":"62","article-title":"Efficacy and safety of Favipiravir, an Oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial","volume":"103","author":"Singh","year":"2020","journal-title":"International Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0750","article-title":"Experimental treatment with Favipiravir for Ebola virus disease (the JIKI trial): A historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Medicine"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0755","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1128\/AAC.01739-09","article-title":"In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 a(H1N1) viruses","volume":"54","author":"Sleeman","year":"2010","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0760","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003565","article-title":"Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: Evidence for proofreading and potential therapeutics","volume":"9","author":"Smith","year":"2013","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0765","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1038\/s41467-020-17240-2","article-title":"Immunological and inflammatory profiles in mild and severe cases of COVID-19","volume":"11","author":"Song","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0770","doi-asserted-by":"crossref","first-page":"759","DOI":"10.15585\/mmwr.mm6924e2","article-title":"Coronavirus disease 2019 case surveillance - United States, January 22-may 30, 2020","volume":"69","author":"Stokes","year":"2020","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0775","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009103","article-title":"A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome","volume":"15","author":"Suemori","year":"2021","journal-title":"PLoS Neglected Tropical Diseases"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0780","doi-asserted-by":"crossref","DOI":"10.1136\/adc.69.6.639","article-title":"Effect of oral acyclovir against primary and secondary viraemia in incubation period of varicella","volume":"69","author":"Suga","year":"1993","journal-title":"Archives of Disease in Childhood"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0785","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S1473-3099(20)30482-5","article-title":"Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the diamond princess cruise ship: A retrospective analysis","volume":"20","author":"Tabata","year":"2020","journal-title":"The Lancet Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0790","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/095632020301400502","article-title":"In vitro and in vivo activities of T-705 and oseltamivir against influenza virus","volume":"14","author":"Takahashi","year":"2003","journal-title":"Antiviral Chemistry & Chemotherapy"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0795","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1016\/S0264-410X(03)00303-7","article-title":"Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay","volume":"21","author":"Takahashi","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0800","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S0140-6736(74)90144-5","article-title":"Live vaccine used to prevent the spread of varicella in children in hospital","volume":"2","author":"Takahashi","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0805","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.antiviral.2016.06.007","article-title":"Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir","volume":"132","author":"Takashita","year":"2016","journal-title":"Antiviral Research"},{"key":"10.1016\/j.pharmthera.2022.108121_bib988","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4149\/av_2017_01_48","article-title":"T-705 (Favipiravir) suppresses tumor necrosis factor alpha production in response to influenza virus infection: A beneficial feature of T-705 as an anti-influenza drug.","volume":"61","author":"Tanaka","year":"2017","journal-title":"Acta Virol"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0810","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202152744","article-title":"Rapid endotheliitis and vascular damage characterize SARS-CoV-2 infection in a human lung-on-chip model","volume":"22","author":"Thacker","year":"2021","journal-title":"EMBO Reports"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0815","author":"The Japanese Association for Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0820","author":"The Japanese Society of Clinical Virology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0825","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with COVID-19","volume":"384","author":"The REMAP-CAP Investigators","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0830","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis","volume":"324","author":"The WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0835","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1164\/rccm.202006-2157CP","article-title":"Why COVID-19 silent hypoxemia is baffling to physicians","volume":"202","author":"Tobin","year":"2020","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0840","series-title":"PMDA report on the deliberation results","article-title":"CTD for Avigan Tablets 200 mg","author":"Toyama-Chemical-Co.-Ltd","year":"2014"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0845","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. US oral neuraminidase study group","volume":"283","author":"Treanor","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0850","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0022-3565(24)29389-7","article-title":"Early augmentation of interleukin (IL)-12 level in the airway of mice administered orally with clarithromycin or intranasally with IL-12 results in alleviation of influenza infection","volume":"298","author":"Tsurita","year":"2001","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0855","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/molehr\/gaq048","article-title":"Telomere lengths in human oocytes, cleavage stage embryos and blastocysts","volume":"16","author":"Turner","year":"2010","journal-title":"Molecular Human Reproduction"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0865","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1128\/AAC.01156-16","article-title":"Distinct effects of T-705 (Favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis","volume":"60","author":"Vanderlinden","year":"2016","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0870","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(20)31103-X","article-title":"An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study","volume":"395","author":"Verdoni","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0875","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1001\/jamapediatrics.2020.4573","article-title":"Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: A systematic review and meta-analysis","volume":"175","author":"Viner","year":"2021","journal-title":"JAMA Pediatrics"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0880","series-title":"Viriom and Chromis publish results of a multi-center open label post-marketing clinical study in 940 COVID-19 patients confirming efficacy of Avifavir at CROI2021","author":"Viriom-Inc","year":"2021"},{"issue":"64\u201375","key":"10.1016\/j.pharmthera.2022.108121_bb0885","article-title":"Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity","volume":"184","author":"Volz","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0890","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","article-title":"SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801","volume":"591","author":"Wahl","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0895","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Research"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0900","doi-asserted-by":"crossref","first-page":"411","DOI":"10.15585\/mmwr.mm6914e1","article-title":"Presymptomatic transmission of SARS-CoV-2 - Singapore, January 23-march 16, 2020","volume":"69","author":"Wei","year":"2020","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0905","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00006454-200102000-00002","article-title":"Oral oseltamivir treatment of influenza in children","volume":"20","author":"Whitley","year":"2001","journal-title":"The Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0910","series-title":"Global surveillance for COVID-19 caused by human infection with COVID-19 virus","author":"WHO","year":"2020"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0915","series-title":"Naming the coronavirus disease (COVID-19) and the virus that causes it","author":"WHO","year":"2020"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0920","series-title":"WHO announces COVID-19 outbreak a pandemic","author":"WHO","year":"2020"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0925","series-title":"COVID-19 vaccines","author":"WHO","year":"2021"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0930","series-title":"COVID-19 weekly epidemiological update","author":"WHO","year":"2021"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0935","author":"WHO"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0940","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.pathol.2020.08.001","article-title":"SARS-CoV-2 in children: Spectrum of disease, transmission and immunopathological underpinnings","volume":"52","author":"Williams","year":"2020","journal-title":"Pathology"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0945","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199403313301304","article-title":"A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster","volume":"330","author":"Wood","year":"1994","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0950","first-page":"79","article-title":"Efficacy of oral acyclovir treatment of acute herpes zoster","volume":"85","author":"Wood","year":"1988","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0955","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"The Lancet Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0960","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2016.12.008","article-title":"Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor","volume":"139","author":"Yajima","year":"2017","journal-title":"Antiviral Research"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0965","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dkh029","article-title":"Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients","volume":"53","author":"Zeldin","year":"2004","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0970","article-title":"Mechanism of action of favipiravir against SARS-CoV-2: Mutagenesis or chain termination?","volume":"2","author":"Zhao","year":"2021","journal-title":"Innovation (N Y)"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0975","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0980","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jiab247","article-title":"Beta-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells","volume":"224","author":"Zhou","year":"2021","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2022.108121_bb0985","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1001\/jamaneurol.2020.2065","article-title":"Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: A review","volume":"77","author":"Zubair","year":"2020","journal-title":"JAMA Neurology"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822000158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822000158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:21:02Z","timestamp":1759011662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725822000158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":201,"alternative-id":["S0163725822000158"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108121","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108121"}}